Security
Rapport Therapeutics, Inc. Common Stock · RAPP
RAPPNASDAQCommon stockCurrentCIK 2012593Updated Oct 4, 2026
Name history
Rapport Therapeutics, Inc. · through Oct 1, 2026
RAPP price & chart
Loading TradingView…
NASDAQ:RAPP on TradingView ↗About the company
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company’s epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders. Availability of Other Information About Rapport Th…
In the news
Seeking Alpha
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade ↗
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania - Slideshow ↗
Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant Success ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 512,431,000Source | 314,933,000Source | 155,423,000Source |
| Property, Plant and Equipment, NetUSD | 2,976,000Source | 3,529,000Source | 1,916,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 52,645,000Source | 56,805,000Source | 70,169,000Source |
| Assets, CurrentUSD | 498,561,000Source | 309,802,000Source | 150,872,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,917,000Source | 4,417,000Source | 3,309,000Source |
| Operating Lease, Right-of-Use AssetUSD | 9,909,000Source | 1,442,000Source | 2,084,000Source |
| Other Assets, NoncurrentUSD | 985,000Source | 160,000Source | 551,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 27,778,000Source | 9,506,000Source | 14,479,000Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 48,000Source | 37,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -235,228,000Source | -123,745,000Source | -45,438,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 546,000Source | -522,000Source | 4,000Source |
| Stockholders' Equity Attributable to ParentUSD | 484,653,000Source | 305,427,000Source | -25,634,000Source |
| Additional Paid in Capital, Common StockUSD | 719,287,000Source | 429,657,000Source | 19,796,000Source |
| Liabilities and EquityUSD | 512,431,000Source | 314,933,000Source | 155,423,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 19,049,000Source | 8,767,000Source | 8,803,000Source |
| Operating Lease, Liability, CurrentUSD | 2,755,000Source | 737,000Source | 670,000Source |
| Accounts Payable, CurrentUSD | 4,190,000Source | 1,954,000Source | 2,502,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,729,000Source | 739,000Source | 1,476,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 12,104,000Source | 6,076,000Source | 5,631,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 490,500,000Source | 305,300,000Source | — |
| Short-term InvestmentsUSD | 437,894,000Source | 248,475,000Source | 77,309,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -111,483,000Source | -78,307,000Source | -34,786,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 1,017,000Source | 839,000Source | 112,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 18,855,000Source | 10,235,000Source | 3,525,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | 2,215,000Source | -346,000Source | 856,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -87,473,000Source | -64,828,000Source | -27,181,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -187,473,000Source | -170,141,000Source | -78,860,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 616,000Source | 2,405,000Source | 1,636,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 270,786,000Source | 221,625,000Source | 145,136,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -4,160,000Source | -13,344,000Source | 39,095,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 18,855,000Source | 10,235,000Source | 3,525,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 490,500,000Source | 305,300,000Source | — |
| DepreciationUSD | 1,000,000Source | 800,000Source | 100,000Source |
| General and Administrative ExpenseUSD | 30,310,000Source | 22,120,000Source | 8,180,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 10,000Source |
| Investment Income, InterestUSD | 13,616,000Source | 12,138,000Source | 2,527,000Source |
| Net Income (Loss) Attributable to ParentUSD | -111,483,000Source | -78,307,000Source | -34,786,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -111,483,000Source | -78,307,000Source | -34,786,000Source |
| Nonoperating Income (Expense)USD | 13,616,000Source | 4,748,000Source | 1,403,000Source |
| Operating ExpensesUSD | 125,099,000Source | 83,055,000Source | 36,179,000Source |
| Payments of Financing CostsUSD | — | — | 134,000Source |
| Payments to Acquire InvestmentsUSD | 354,784,000Source | 377,532,000Source | 77,224,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 54,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,348,000Source | 7,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -125,099,000Source | -83,055,000Source | -36,179,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | -78,307,000Source | -34,776,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 10,000Source |
| Net Income (Loss) Attributable to ParentUSD | -111,483,000Source | -78,307,000Source | -34,786,000Source |
| Earnings Per Share, BasicUSD per share | -2.86Source | -3.78Source | -23.1Source |
| Earnings Per Share, DilutedUSD per share | -2.86Source | -3.78Source | -23.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 38,934,569Source | 20,738,338Source | 1,505,774Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 38,934,569Source | 20,738,338Source | 1,505,774Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 30,310,000Source | 22,120,000Source | 8,180,000Source |
| Investment Income, InterestUSD | 13,616,000Source | 12,138,000Source | 2,527,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -111,483,000Source | -78,307,000Source | -34,786,000Source |
| Nonoperating Income (Expense)USD | 13,616,000Source | 4,748,000Source | 1,403,000Source |
| Operating ExpensesUSD | 125,099,000Source | 83,055,000Source | 36,179,000Source |
| Research and Development ExpenseUSD | 94,789,000Source | 60,935,000Source | 27,999,000Source |
Offerings
Registration 333-294170
Filing attachments
rapp-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 n…
Read attachment ↗rapp-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 p…
Read attachment ↗rapp-ex99_1.htm · 8-K · 2026-04-21
EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13-16 New…
Read attachment ↗rapp-ex99_2.htm · 8-K · 2026-04-21
EX-99.2 3 rapp-ex99_2.htm EX-99.2 April 2026 Corporate Presentation This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-loo…
Read attachment ↗d46288dex47.htm · S-3ASR · 2026-03-10
Exhibit 4.7 RAPPORT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [• ], 202[• ] Senior Debt Securities TABLE OF CONTENTS 1 ARTICLE 1 DEFINITIONS ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF …
Read attachment ↗d46288dex48.htm · S-3ASR · 2026-03-10
Exhibit 4.8 RAPPORT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [• ], 202[• ] Subordinated Debt Securities TABLE OF CONTENTS 1 ARTICLE 1 DEFINITIONS ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITI…
Read attachment ↗